Literature DB >> 1682066

Compartmentation of cAMP in adult canine ventricular myocytes. Relation to single-cell free Ca2+ transients.

C M Hohl1, Q A Li.   

Abstract

Isolated adult canine ventricular myocytes were used to study the role of compartmentation of cAMP in the diverse functional responses to various drugs that elevate cAMP. Myocytes presented with the beta-agonist isoproterenol accumulated cAMP with a half maximally effective concentration (EC50) of 3.55 x 10(-8) M. Approximately 45% of the total cAMP was recovered in the particulate fraction of digitonin-lysed myocytes under these conditions. With phosphodiesterase inhibition (10 microM isobutylmethylxanthine), isoproterenol-stimulated cAMP production was up to 3.4-fold greater, but the proportion of total cAMP residing in the particulate fraction declined to less than 20%. Similar results were obtained with forskolin, a direct activator of adenylate cyclase. Treatment with isoproterenol shortened the duration at 50% maximum peak height (T 1/2) and increased the peak fluorescence ratio of electrically triggered single-cell free Ca2+ transients in fura-2-loaded canine myocytes. Isoproterenol dose-response curves gave EC50 values of 1.7 x 10(-9) and 4.4 x 10(-9) M for effects on T 1/2 and peak height, respectively. Alterations in peak height and T 1/2 of Ca2+ transients also showed a dose dependency on isobutylmethylxanthine and forskolin. Comparison of myocyte cAMP content with the corresponding changes in free Ca2+ transients demonstrated a close correlation between particulate cAMP and the extent of shortening or increase in peak height of the fura-2 Ca2+ transients (r = 0.92 for each). However, when these two parameters were plotted as a function of total cAMP, the resulting curves were nonlinear and divergent for each agent tested. The results support the hypothesis that differences in responses to agents that augment cAMP can be explained in part by compartmentation of cAMP. Furthermore, Ca2+ mobilization seems to be most affected by cAMP located in the particulate compartment of canine cardiac myocytes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1682066     DOI: 10.1161/01.res.69.5.1369

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  25 in total

1.  Effects of pharmacological preconditioning with U50488H on calcium homeostasis in rat ventricular myocytes subjected to metabolic inhibition and anoxia.

Authors:  J C S Ho; S Wu; K W L Kam; J S K Sham; T M Wong
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

2.  Systems analysis of PKA-mediated phosphorylation gradients in live cardiac myocytes.

Authors:  Jeffrey J Saucerman; Jin Zhang; Jody C Martin; Lili X Peng; Antine E Stenbit; Roger Y Tsien; Andrew D McCulloch
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-11       Impact factor: 11.205

3.  Poster communications.

Authors: 
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

Review 4.  Supramolecular assemblies and localized regulation of voltage-gated ion channels.

Authors:  Shuiping Dai; Duane D Hall; Johannes W Hell
Journal:  Physiol Rev       Date:  2009-04       Impact factor: 37.312

5.  Ca2+ mobilization in fetal-human cardiac myocytes is stimulated by isoproterenol and inhibited by ryanodine.

Authors:  M Toraason; D E Richards; P I Mathias
Journal:  In Vitro Cell Dev Biol Anim       Date:  1998-01       Impact factor: 2.416

6.  A compartmentalized mathematical model of the β1-adrenergic signaling system in mouse ventricular myocytes.

Authors:  Vladimir E Bondarenko
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

7.  Effects of cyclic GMP elevation on isoprenaline-induced increase in cyclic AMP and relaxation in rat aortic smooth muscle: role of phosphodiesterase 3.

Authors:  E Delpy; H Coste; A C Gouville
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

8.  Cardiotonic actions of selective phosphodiesterase inhibitors in rat isolated ventricular cardiomyocytes.

Authors:  E J Kelso; B J McDermott; B Silke
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

Review 9.  Phosphodiesterase inhibition in heart failure.

Authors:  Matthew Movsesian; Josef Stehlik; Fabrice Vandeput; Michael R Bristow
Journal:  Heart Fail Rev       Date:  2008-12-19       Impact factor: 4.214

10.  Cardiovascular effects of a novel, potent and selective phosphodiesterase 5 inhibitor, DMPPO: in vitro and in vivo characterization.

Authors:  E Delpy; A C le Monnier de Gouville
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.